Spyre Therapeutics Inc.
NASDAQ:SYRE
Spyre Therapeutics Inc. Stock, NASDAQ:SYRE
Building 17, 221 Crescent Street, Waltham, Massachusetts 02453
United States of America
Phone: +1.617.651.5940
Number of Employees: 65
Description
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.